Details of the Drug
- Generic Name:
- Drug Type:
- Bispecific CD20-directed CD3 T-cell engager
- How the Drug is Given:
Injection, for intravenous use
Indications and Usage
Mosunetuzumab-axgb is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Side effects needing medical attention
The most common adverse reactions include cytokine release syndrome, fever, chills, low blood pressure, fast or irregular heartbeat, tiredness or weakness, difficulty breathing, headache, confusion, feeling anxious, dizziness or light-headedness, nausea, vomiting, rash.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.